Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RGEN | US
3.54
3.10%
Healthcare
Biotechnology
30/06/2024
24/04/2026
117.60
115.15
118.31
111.45
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America Europe the Asia Pacific and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening viral clearance validation studies and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition the company provides filtration products such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes which are used in downstream biologic drug concentration buffer exchange and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products and ProConnex TFDF flow paths. Further it provides process analytics products such as slope spectroscopy systems under the SoloVPE FlowVPE and FlowVPX brands. The company sells its products to life sciences biopharmaceutical and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham Massachusetts.
View LessStrength based on increasing price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
70.0%1 month
56.2%3 months
46.5%6 months
41.5%-
82.64
4.14
0.37
0.26
88.78
13.55
2.59
78.94M
6.59B
6.59B
-
1.60
-83.00
-3.20
-0.10
4.25
7.94
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
31.93
Range1M
31.93
Range3M
60.26
Rel. volume
1.34
Price X volume
145.16M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Grifols S.A | GRFS | Biotechnology | 8.08 | 6.31B | 1.13% | 33.27 | 190.24% |
| Arcellx Inc. Common Stock | ACLX | Biotechnology | 115.03 | 6.18B | -0.02% | n/a | 15.25% |
| Praxis Precision Medicines Inc | PRAX | Biotechnology | 344.82 | 6.12B | 4.62% | n/a | 0.46% |
| Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 6.75 | 6.10B | -2.74% | n/a | 6.83% |
| Protagonist Therapeutics Inc | PTGX | Biotechnology | 100 | 5.89B | -2.55% | 17.27 | 2.03% |
| Amarin Corporation plc | AMRN | Biotechnology | 14.31 | 5.88B | -1.92% | n/a | 1.47% |
| Erasca Inc. Common Stock | ERAS | Biotechnology | 21.49 | 5.84B | -4.36% | n/a | 11.96% |
| Lyell Immunopharma Inc. Common Stock | LYEL | Biotechnology | 22.41 | 5.74B | -5.04% | n/a | 10.63% |
| TG Therapeutics Inc | TGTX | Biotechnology | 36.62 | 5.67B | -0.81% | 34.28 | 63.38% |
| Alkermes plc | ALKS | Biotechnology | 33.31 | 5.49B | -1.77% | 12.40 | 28.66% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 88.78 | 0.53 | Expensive |
| Ent. to Revenue | 13.55 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.14 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 46.46 | 72.80 | Lower Risk |
| Debt to Equity | 0.37 | -1.23 | Expensive |
| Debt to Assets | 0.26 | 0.25 | Par |
| Market Cap | 6.59B | 3.66B | Market Leader |